We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current TBPH market cap is 432.52M. The company's latest EPS is USD -1.1459 and P/E is -7.84.
Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 14.65M | 10.42M | 13.75M | 15.69M | 17.57M |
Operating Income | -17.43M | -24.91M | -16.12M | -8.76M | -6.24M |
Net Income | -10.36M | -22.09M | -15.65M | -8.95M | -8.51M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 73.41M | 71.86M | 55.31M | 51.35M | 57.42M |
Operating Income | -218.21M | -229.32M | -153.8M | -91.96M | -56.04M |
Net Income | -236.46M | -278.02M | -199.43M | 872.13M | -55.19M |
Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 607.4M | 538.55M | 446.63M | 413.59M | 382M |
Total Liabilities | 165.6M | 167.99M | 166.47M | 167.46M | 169M |
Total Equity | 441.8M | 370.56M | 280.16M | 246.13M | 213M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 408.83M | 469.06M | 374.82M | 607.4M | 382M |
Total Liabilities | 632.67M | 772.81M | 713.39M | 165.6M | 169M |
Total Equity | -223.84M | -303.75M | -338.57M | 441.8M | 213M |
Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -186.99M | -11.22M | -23.66M | -26.14M | -27M |
Investing | 1.15B | -43.05M | -32M | -32.02M | -32.7M |
Financing | -758.81M | -56.24M | -136.92M | -168.32M | -198.93M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -238.2M | -250.4M | -207.86M | -186.99M | -27M |
Investing | -83.05M | 10.72M | 124.49M | 1.15B | -32.7M |
Financing | 1.29M | 251.62M | 91.86M | -758.81M | -198.93M |
Market Cap | 432.52M |
Price to Earnings Ratio | -7.84 |
Price to Sales Ratio | 7.53 |
Price to Cash Ratio | 10.94 |
Price to Book Ratio | 2.03 |
Dividend Yield | - |
Shares Outstanding | 48.16M |
Average Volume (1 week) | 334.08k |
Average Volume (1 Month) | 421.71k |
52 Week Change | -17.92% |
52 Week High | 11.71 |
52 Week Low | 8.21 |
Spread (Intraday) | 5.49 (38.23%) |
Company Name | Theravance Biopharma Inc |
Address |
p.o. box 309 george town KY1-1104 |
Website | https://www.theravance.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions